ISSN: 2577-4379
Authors: Khan MN* and Kumar A
In the past decades, our knowledge about the relationship between cancer and the immune system has increased considerably. Immunotherapy has been a promising and rapidly evolving field in cancer treatment. However, keep in mind that the information might have advanced since then. Drugs like pembrolizumab and nivolumab, which target PD-1/PD-L1 pathways, have shown success in treating various cancers. These drugs release the brakes on the immune system, allowing it to better recognize and attack cancer cells. This involves harvesting and modifying a patient’s immune cells outside the body before infusing them back to target cancer cells. Researchers are exploring combinations of different immunotherapies and traditional treatments to enhance effectiveness and overcome resistance. Efforts to identify predictive biomarkers aim to personalize immunotherapy, ensuring it benefits patients who are most likely to respond. In summary, immunotherapy has made significant strides in cancer treatment, with ongoing research focusing on refining existing therapies, discovering new targets, and expanding the range of treatable cancers. The prospectus is promising, but addressing challenges remains critical for realizing the full potential of immunotherapy in the fight against cancer.
Keywords: Immune System; Target Inhibitor; Checkpoint; Antibody; Immunotherapy; Types Of Cancer
